Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 163
Filter
Add more filters

Publication year range
2.
Hum Mol Genet ; 24(13): 3732-41, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-25855803

ABSTRACT

Polymicrogyria (PMG) is a structural brain abnormality involving the cerebral cortex that results from impaired neuronal migration and although several genes have been implicated, many cases remain unsolved. In this study, exome sequencing in a family where three fetuses had all been diagnosed with PMG and cerebellar hypoplasia allowed us to identify regions of the genome for which both chromosomes were shared identical-by-descent, reducing the search space for causative variants to 8.6% of the genome. In these regions, the only plausibly pathogenic mutations were compound heterozygous variants in PI4KA, which Sanger sequencing confirmed segregated consistent with autosomal recessive inheritance. The paternally transmitted variant predicted a premature stop mutation (c.2386C>T; p.R796X), whereas the maternally transmitted variant predicted a missense substitution (c.5560G>A; p.D1854N) at a conserved residue within the catalytic domain. Functional studies using expressed wild-type or mutant PI4KA enzyme confirmed the importance of p.D1854 for kinase activity. Our results emphasize the importance of phosphoinositide signalling in early brain development.


Subject(s)
Arthrogryposis/enzymology , Cerebellum/abnormalities , Fetal Diseases/enzymology , Germ-Line Mutation , Nervous System Malformations/enzymology , Phosphotransferases (Alcohol Group Acceptor)/genetics , Polymicrogyria/enzymology , Amino Acid Sequence , Arthrogryposis/embryology , Arthrogryposis/genetics , Base Sequence , Brain/embryology , Brain/enzymology , Cerebellum/embryology , Cerebellum/enzymology , Developmental Disabilities/enzymology , Developmental Disabilities/genetics , Exome , Female , Fetal Diseases/genetics , Humans , Infant , Male , Minor Histocompatibility Antigens , Molecular Sequence Data , Mutation, Missense , Nervous System Malformations/embryology , Nervous System Malformations/genetics , Pedigree , Phosphotransferases (Alcohol Group Acceptor)/chemistry , Polymicrogyria/embryology , Polymicrogyria/genetics , Polymorphism, Single Nucleotide , Sequence Alignment
3.
Am J Gastroenterol ; 112(6): 838-846, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28291236

ABSTRACT

Acute fatty liver of pregnancy (AFLP) is an obstetric emergency characterized by maternal liver failure and may have complications for the mother and fetus, including death. This review examines recent literature on the epidemiology, pathogenesis, diagnosis, and treatment of acute fatty liver of pregnancy. Pathogenesis of this disease has been linked to defects in fatty acid metabolism during pregnancy, especially in the setting of fetal genetic defects in fatty acid oxidation. The value of screening all patients for these genetic defects remains to be determined. Distinguishing AFLP from other high-risk liver diseases of pregnancy that have overlap features, such as HELLP and preeclampsia, can be challenging. Although sensitive diagnostic tools such as the Swansea criteria have been developed, further work is needed to diagnose AFLP more quickly. Although survival rates have improved in the past 30 years, delay in diagnosis and treatment of AFLP has life-threatening consequences; an algorithmic approach to AFLP may be a valuable resource for clinicians. Future epidemiological and long-term studies will improve our prediction of women at risk for developing AFLP and determine the long-term consequences of this condition.


Subject(s)
3-Hydroxyacyl-CoA Dehydrogenase/deficiency , Fatty Liver/diagnosis , Fatty Liver/genetics , Fetal Diseases/physiopathology , Pregnancy Complications/diagnosis , Pregnancy Complications/genetics , 3-Hydroxyacyl-CoA Dehydrogenase/genetics , Acute Disease , Diagnosis, Differential , Fatty Liver/epidemiology , Fatty Liver/therapy , Female , Fetal Diseases/diagnosis , Fetal Diseases/enzymology , Humans , Liver Failure, Acute/etiology , Pregnancy , Pregnancy Complications/epidemiology , Pregnancy Complications/therapy , Risk Factors
4.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi ; 31(6): 686-92, 2014 Dec.
Article in Zh | MEDLINE | ID: mdl-25449068

ABSTRACT

OBJECTIVE: To characterize the mutation spectrum of phenylalanine hydroxylase (PAH) gene and perform prenatal diagnosis for families with classical phenylketonuria. METHODS: By stratified sequencing, mutations were detected in the exons and flaking introns of PAH gene of 44 families with classical phenylketonuria. 47 fetuses were diagnosed by combined sequencing with linkage analysis of three common short tandem repeats (STR) (PAH-STR, PAH-26 and PAH-32) in the PAH gene. RESULTS: Thirty-one types of mutations were identified. A total of 84 mutations were identified in 88 alleles (95.45%), in which the most common mutation have been R243Q (21.59%), EX6-96A>G (6.82%), IVS4-1G>A (5.86%) and IVS7+2T>A (5.86%). Most mutations were found in exons 3, 5, 6, 7, 11 and 12. The polymorphism information content (PIC) of these three STR markers was 0.71 (PAH-STR), 0.48 (PAH-26) and 0.40 (PAH-32), respectively. Prenatal diagnosis was performed successfully with the combined method in 47 fetuses of 44 classical phenylketonuria families. Among them, 11 (23.4%) were diagnosed as affected, 24 (51.1%) as carriers, and 12 (25.5%) as unaffected. CONCLUSION: Prenatal diagnosis can be achieved efficiently and accurately by stratified sequencing of PAH gene and linkage analysis of STR for classical phenylketonuria families.


Subject(s)
Fetal Diseases/enzymology , Phenylalanine Hydroxylase/genetics , Phenylketonurias/diagnosis , Phenylketonurias/enzymology , Point Mutation , Adolescent , Adult , Case-Control Studies , Child , Child, Preschool , Female , Fetal Diseases/diagnosis , Fetal Diseases/genetics , Genetic Testing , Humans , Infant , Infant, Newborn , Male , Microsatellite Repeats , Middle Aged , Pedigree , Phenylketonurias/genetics , Pregnancy , Prenatal Diagnosis , Young Adult
5.
Toxicol Appl Pharmacol ; 252(1): 55-61, 2011 Apr 01.
Article in English | MEDLINE | ID: mdl-21295602

ABSTRACT

The mechanisms underlying the teratogenicity of methanol (MeOH) in rodents, unlike its acute toxicity in humans, are unclear, but may involve reactive oxygen species (ROS). Embryonic catalase, although expressed at about 5% of maternal activity, may protect the embryo by detoxifying ROS. This hypothesis was investigated in whole embryo culture to remove confounding maternal factors, including metabolism of MeOH by maternal catalase. C57BL/6 (C57) mouse embryos expressing human catalase (hCat) or their wild-type (C57 WT) controls, and C3Ga.Cg-Catb/J acatalasemic (aCat) mouse embryos or their wild-type C3HeB/FeJ (C3H WT) controls, were explanted on gestational day (GD) 9 (plug=GD 1), exposed for 24 h to 4 mg/ml MeOH or vehicle, and evaluated for functional and morphological changes. hCat and C57 WT vehicle-exposed embryos developed normally. MeOH was embryopathic in C57 WT embryos, evidenced by decreases in anterior neuropore closure, somites developed and turning, whereas hCat embryos were protected. Vehicle-exposed aCat mouse embryos had lower yolk sac diameters compared to C3H WT controls, suggesting that endogenous ROS are embryopathic. MeOH was more embryopathic in aCat embryos than WT controls, with reduced anterior neuropore closure and head length only in catalase-deficient embryos. These data suggest that ROS may be involved in the embryopathic mechanism of methanol, and that embryonic catalase activity may be a determinant of teratological risk.


Subject(s)
Catalase/biosynthesis , Fetal Diseases/enzymology , Gene Expression Regulation, Enzymologic/drug effects , Methanol/toxicity , Mutation/genetics , Acatalasia/enzymology , Acatalasia/genetics , Animals , Catalase/genetics , Embryo, Mammalian , Female , Fetal Diseases/chemically induced , Humans , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Transgenic , Pregnancy
6.
Am J Bioeth ; 10(9): 35-45, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20818559

ABSTRACT

On February 3, 2010, a "Letter of Concern from Bioethicists," organized by fetaldex.org, was sent to report suspected violations of the ethics of human subjects research in the off-label use of dexamethasone during pregnancy by Dr. Maria New. Copies of this letter were submitted to the FDA Office of Pediatric Therapeutics, the Department of Health and Human Services (DHHS) Office for Human Research Protections, and three universities where Dr. New has held or holds appointments. We provide a critical appraisal of the Letter of Concern and show that it makes false claims, misrepresents scientific publications and websites, fails to meet standards of evidence-based reasoning, makes undocumented claims, treats as settled matters what are, instead, ongoing controversies, offers "mere opinion" as a substitute for argument, and makes contradictory claims. The Letter of Concern is a case study in unethical transgressive bioethics. We call on fetaldex.org to withdraw the letter and for co-signatories to withdraw their approval of it.


Subject(s)
Adrenal Hyperplasia, Congenital/diagnosis , Adrenal Hyperplasia, Congenital/drug therapy , Correspondence as Topic , Dexamethasone/administration & dosage , Disorders of Sex Development/prevention & control , Ethicists/standards , Fetal Diseases/drug therapy , Genitalia, Female/abnormalities , Off-Label Use , Prenatal Diagnosis , Therapeutic Human Experimentation/ethics , Adrenal Hyperplasia, Congenital/complications , Adrenal Hyperplasia, Congenital/enzymology , Clinical Trials as Topic , Disorders of Sex Development/etiology , Drug Administration Schedule , Ethics Committees, Research , Female , Fetal Diseases/diagnosis , Fetal Diseases/enzymology , Genitalia, Female/surgery , Glucocorticoids/administration & dosage , Humans , Informed Consent/ethics , Male , Off-Label Use/ethics , Pregnancy , Plastic Surgery Procedures , Referral and Consultation , Steroid 21-Hydroxylase/metabolism , United States , United States Food and Drug Administration , Virilism/prevention & control
7.
Am J Clin Nutr ; 109(3): 674-683, 2019 03 01.
Article in English | MEDLINE | ID: mdl-30848279

ABSTRACT

BACKGROUND: The risk of neural tube defects (NTDs) is influenced by nutritional factors and genetic determinants of one-carbon metabolism. A key pathway of this metabolism is the vitamin B-12- and folate-dependent remethylation of homocysteine, which depends on methionine synthase (MS, encoded by MTR), methionine synthase reductase, and methylenetetrahydrofolate reductase. Methionine, the product of this pathway, is the direct precursor of S-adenosylmethionine (SAM), the universal methyl donor needed for epigenetic mechanisms. OBJECTIVES: This study aimed to evaluate whether the availability of vitamin B-12 and folate and the expression or activity of the target enzymes of the remethylation pathway are involved in NTD risk. METHODS: We studied folate and vitamin B-12 concentrations and activity, expression, and gene variants of the 3 enzymes in liver from 14 NTD and 16 non-NTD fetuses. We replicated the main findings in cord blood from pregnancies of 41 NTD fetuses compared with 21 fetuses with polymalformations (metabolic and genetic findings) and 375 control pregnancies (genetic findings). RESULTS: The tissue concentration of vitamin B-12 (P = 0.003), but not folate, and the activity (P = 0.001), transcriptional level (P = 0.016), and protein expression (P = 0.003) of MS were decreased and the truncated inactive isoforms of MS were increased in NTD livers. SAM was significantly correlated with MS activity and vitamin B-12. A gene variant in exon 1 of GIF (Gastric Intrinsic Factor gene) was associated with a dramatic decrease of liver vitamin B-12 in 2 cases. We confirmed the decreased vitamin B-12 in cord blood from NTD pregnancies. A gene variant of GIF exon 3 was associated with NTD risk. CONCLUSIONS: The decreased vitamin B-12 in liver and cord blood and decreased expression and activity of MS in liver point out the impaired remethylation pathway as hallmarks associated with NTD risk. We suggest evaluating vitamin B-12 in the nutritional recommendations for prevention of NTD risk beside folate fortification or supplementation.


Subject(s)
5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/genetics , Fetal Diseases/enzymology , Liver/metabolism , Neural Tube Defects/enzymology , Vitamin B 12/metabolism , 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/metabolism , Case-Control Studies , Female , Ferredoxin-NADP Reductase/genetics , Ferredoxin-NADP Reductase/metabolism , Fetal Diseases/genetics , Fetal Diseases/metabolism , Folic Acid/analysis , Folic Acid/metabolism , Gestational Age , Humans , Liver/chemistry , Liver/embryology , Liver/enzymology , Male , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/metabolism , Neural Tube Defects/embryology , Neural Tube Defects/genetics , Neural Tube Defects/metabolism , Pregnancy , Vitamin B 12/analysis
8.
Mol Genet Metab ; 94(4): 428-430, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18485779

ABSTRACT

Because of a switch in energy-producing substrate utilization from glucose in the fetal period to fatty acids postnatally, intrauterine morbidity of fatty acid oxidation defects has widely been denied. We report the intrauterine development of severe cardiomyopathy in a child with mitochondrial trifunctional protein deficiency after 27 weeks of gestation. The child was born at 31 weeks of gestation and died on day 3 of life. Severe cardiac mitochondrial proliferation was observed. Molecular analysis of both TFP genes was performed and confirmed a homozygous mutation in the TFP alpha-subunit introducing a stop codon at amino acid position 256 (g.871C>T, p.R256X). Despite severe intrauterine decompensation in our patient, no HELLP-syndrome or acute fatty liver of pregnancy was observed in the mother. In the pathogenesis of maternal HELLP-syndrome, toxic effects of accumulating long-chain hydroxy-acyl-CoAs or long-chain hydroxy-acylcarnitines are suspected. In our patient, acylcarnitine analysis on day 2 of life during severest metabolic decompensation did not reveal massive accumulation of long-chain hydroxy-acylcarnitines in blood, suggesting other pathogenic factors than toxic effects. The most important pathogenic mechanism for the development of intrauterine cardiomyopathy appears to be significant cardiac energy deficiency. In conclusion, our report implicates that fatty acid oxidation does play a significant role during intrauterine development with special regard to the heart. Severe cardiac mitochondrial proliferation in TFP deficiency suggests pathophysiologically relevant energy deficiency in this condition.


Subject(s)
Cardiomyopathies/physiopathology , Cell Proliferation , Mitochondria/physiology , Multienzyme Complexes/deficiency , Muscle Cells/physiology , Prenatal Diagnosis , Cardiomyopathies/enzymology , Cardiomyopathies/genetics , Codon, Nonsense , Consanguinity , Fatal Outcome , Fatty Acids/metabolism , Female , Fetal Diseases/enzymology , Fetal Diseases/genetics , Fetal Diseases/physiopathology , Humans , Infant, Newborn , Metabolism, Inborn Errors/enzymology , Metabolism, Inborn Errors/genetics , Metabolism, Inborn Errors/pathology , Metabolism, Inborn Errors/physiopathology , Mitochondria/enzymology , Mitochondria/genetics , Mitochondrial Trifunctional Protein , Multienzyme Complexes/genetics , Muscle Cells/cytology , Muscle Cells/enzymology , Muscle Cells/pathology , Oxidation-Reduction , Pregnancy
9.
Brain Res ; 1200: 138-45, 2008 Mar 20.
Article in English | MEDLINE | ID: mdl-18289516

ABSTRACT

Intrauterine inflammation has been implicated in developmental brain injuries, including the development of periventricular leukomalacia (PVL) and cerebral palsy (CP). Previous studies in our rat model of intrauterine inflammation demonstrated apoptotic cell death in fetal brains within the first 5 days after lipopolysaccharide (LPS) administration to mothers and eventual dysmyelination. Cysteine-containing, aspartate-specific proteases, or caspases, are proteins involved with apoptosis through both intracellular (intrinsic pathway) and extracellular (extrinsic pathway) mechanisms. We hypothesized that cell death in our model would occur mainly via activation of the extrinsic pathway. We further hypothesized that Fas, a member of the tumor necrosis factor receptor (TNFR) superfamily, would be increased and the death inducing signaling complex (DISC) would be detectable. Pregnant rats were injected intracervically with LPS at E15 and immunoblotting, immunohistochemical and immunoprecipitation analyses were performed. The presence of the activated form of the effector caspase (caspase-3) was observed 24 h after LPS administration. Caspase activity assays demonstrated rapid increases in (i) caspases-9 and -10 within 1 h, (ii) caspase-8 at 2 h and (iii) caspase-3 at 4 h. At 24 h after LPS, activated caspase-3(+)/Fas(+) cells were observed within the developing white matter. Lastly, the DISC complex (caspase-8, Fas and Fas-associated death domain (FADD)) was observed within 30 min by immunoprecipitation. Apoptosis in our model occurs via both extrinsic and intrinsic pathways, and activation of Fas may play a role. Understanding the mechanisms of cell death in models of intrauterine inflammation may affect development of future strategies to mitigate these injuries in children.


Subject(s)
Apoptosis , Caspases/metabolism , Encephalitis/enzymology , Fetal Diseases/enzymology , Nerve Degeneration/enzymology , fas Receptor/metabolism , Animals , Cerebral Palsy/enzymology , Cerebral Palsy/etiology , Cerebral Palsy/physiopathology , Death Domain Receptor Signaling Adaptor Proteins/metabolism , Disease Models, Animal , Encephalitis/chemically induced , Encephalitis/pathology , Enzyme Activation , Fas-Associated Death Domain Protein/metabolism , Female , Fetal Diseases/chemically induced , Fetal Diseases/pathology , Humans , Infant, Newborn , Inflammation Mediators , Isoenzymes/metabolism , Leukomalacia, Periventricular/enzymology , Leukomalacia, Periventricular/etiology , Leukomalacia, Periventricular/physiopathology , Lipopolysaccharides , Nerve Degeneration/chemically induced , Nerve Degeneration/etiology , Pregnancy , Rats , Signal Transduction
10.
J Matern Fetal Neonatal Med ; 30(3): 284-293, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27018008

ABSTRACT

Glucococorticoids play a critical role in the developmental programing and fetal growth. Key molecules mediating and regulating tissue-specific glucocorticoid actions are 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 1 and 2 isozymes, both of which are expressed in the placenta and the fetal membranes. 11beta-HSD1 is implicated in the pathogenesis of metabolic syndrome and its dysregulation has been observed in pregnancy-related complications (pre-eclampsia, intrauterine growth restriction). Interestingly, preliminary clinical data have associated certain 11beta-HSD1 gene polymorphisms with hypertensive disorders in pregnancy, suggesting, if confirmed by further targeted studies, it's potential as a putative prognostic marker. Animal studies and observations in humans have confirmed that 11beta-HSD2 insufficiency is related with pregnancy adversity (pre-eclampsia, intrauterine growth restriction, preterm birth). Importantly, down-regulation or deficiency of placental 11beta-HSD2 is associated with significant restriction in fetal growth and low-birth weight, and unfavorable cardio-metabolic profile in adulthood. The potential association of 11beta-HSD1 tissue-specific dysregulation with gestational diabetes, as well as the plausible utility of 11beta-HSD2, as a biomarker of pregnancy adversity and later life morbidity, are emerging areas of intense scientific interest and future investigation.


Subject(s)
11-beta-Hydroxysteroid Dehydrogenase Type 1/metabolism , 11-beta-Hydroxysteroid Dehydrogenase Type 2/metabolism , Fetal Diseases/enzymology , Pregnancy Complications/enzymology , 11-beta-Hydroxysteroid Dehydrogenase Type 1/genetics , 11-beta-Hydroxysteroid Dehydrogenase Type 2/genetics , Down-Regulation , Epigenesis, Genetic , Female , Fetal Diseases/genetics , Humans , Placenta/enzymology , Polymorphism, Genetic , Pregnancy , Pregnancy Complications/genetics , Prenatal Exposure Delayed Effects/enzymology , Prenatal Exposure Delayed Effects/genetics
11.
J Clin Endocrinol Metab ; 91(1): 248-55, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16249288

ABSTRACT

CONTEXT: Obesity and diabetes during pregnancy are associated with increased insulin resistance and higher neonatal adiposity. In turn, insulin resistance triggers inflammatory pathways with accumulation of placental cytokines. OBJECTIVE: To determine placental signals that translate into development of excess adipose tissue, we investigated the role of phospholipases A2 (PLA2) as targets of inflammatory mediators. SETTING: The study was conducted at Case Western Reserve University, Department of Reproductive Biology. SUBJECTS: Volunteers gave informed written consent in accordance with the Institutional Review Board guidelines. Placenta and cord blood samples were obtained at the time of elective cesarean section in 15 term pregnancies. INTERVENTION: Neonatal anthropometric measurements were performed within 48 h of delivery. Placentas were grouped based on neonatal percentage body fat as obese (body fat > or = 16%) and lean control (body fat < or = 8%). MAIN OUTCOME MEASURES: The primary outcomes were placenta PLA2 expression and fatty acid concentration. RESULTS: Expression of PLA2G2A and PLA2G5, the main placenta phospholipases, was greater (P < 0.05) in placenta of obese compared with control neonates and was associated with increased 20:3 and 20:5 omega-3 polyunsaturated fatty acids. TNF-alpha and leptin content was increased 3-fold in placenta of obese neonates. TNF-alpha and leptin both induced a time-dependent activation of PLA2G2 and PLA2G5 in placental cells. CONCLUSION: Accumulation of omega-3 fatty acids through secretory PLA2 activation is associated with high neonatal adiposity. We propose that the generation of placental lipid mediators through TNF-alpha and leptin stimulation represents a key mechanism to favor excess fetal fat accretion.


Subject(s)
Fetal Diseases/enzymology , Fetal Diseases/physiopathology , Lipids/physiology , Obesity/enzymology , Obesity/physiopathology , Phospholipases A/metabolism , Placenta/physiology , Adult , Cell Separation , Cells, Cultured , Enzyme Activation , Fatty Acids, Omega-3/metabolism , Fatty Acids, Omega-6/metabolism , Female , Humans , Infant, Newborn , Leptin/blood , Phospholipases A2 , Placenta/cytology , Placenta/enzymology , Pregnancy , RNA/biosynthesis , Tumor Necrosis Factor-alpha/metabolism
12.
Prostaglandins Other Lipid Mediat ; 79(1-2): 34-42, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16516808

ABSTRACT

We studied the transplacental ductal constrictive effects of a selective cyclooxygenase (COX)-1 inhibitor (SC560), six selective COX-2 inhibitors including rofecoxib, and a non-selective COX inhibitor (indomethacin). Each drug was administered to the pregnant rats, and fetal ductus arteriosus (DA) was studied with a whole-body freezing method. The inner diameter ratio of the DA to the main pulmonary artery (DA/PA) was 1.02+/-0.03 (mean+/-S.E.M.) in controls. Every drug constricted the DA dose-dependently. In preterm rats on the 19th day of gestation, 10mg/kg of SC560, rofecoxib and indomethacin caused ductal constriction, with DA/PA reduced to 0.76+/-0.02, 0.80+/-0.03 and 0.75+/-0.02, respectively. In near-term on the 21st day, 10mg/kg of them caused ductal constriction, with DA/PA to 0.74+/-0.04, 0.26+/-0.02 and 0.33+/-0.05. In conclusion, both COX-1 and COX-2 selective inhibitors constrict fetal DA. They are not better alternatives for the fetus than non-selective COX inhibitors for tocolysis.


Subject(s)
Cyclooxygenase Inhibitors/adverse effects , Ductus Arteriosus, Patent/physiopathology , Fetal Diseases/physiopathology , Tocolysis/adverse effects , Vasoconstriction/drug effects , Animals , Cyclooxygenase 1/metabolism , Cyclooxygenase 2/metabolism , Cyclooxygenase Inhibitors/administration & dosage , Dose-Response Relationship, Drug , Ductus Arteriosus, Patent/chemically induced , Ductus Arteriosus, Patent/enzymology , Female , Fetal Diseases/chemically induced , Fetal Diseases/enzymology , Fetus/abnormalities , Fetus/enzymology , Fetus/pathology , Fetus/physiopathology , Pregnancy , Rats , Rats, Wistar
13.
Early Hum Dev ; 82(1): 23-8, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16427219

ABSTRACT

The renin-angiotensin system plays an important role in the regulation of blood pressure. The use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers both control hypertension by interruption of the production or action of angiotensin II, the major end-product of the renin-angiotensin system. The use of angiotensin converting enzyme inhibitors in pregnant women revealed serious and deleterious effects on fetal development including renal failure, renal dysplasia, hypotension, oligohydramnios, pulmonary hypoplasia, and hypocalvaria. The fetal effects of angiotensin converting enzyme inhibitors seem to be greatest during the 2nd and 3rd trimesters of pregnancy. The fetal effect of angiotensin converting enzyme inhibitors during the 1st trimester is controversial. These effects may represent the effect of hypoperfusion in the fetus and not a teratogenic effect. The effect of angiotensin receptor blockers is similar to converting enzyme inhibitors. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers should be avoided in all pregnant women. Alternative antihypertensive medications should be considered for use in women of childbearing years.


Subject(s)
Abnormalities, Drug-Induced/etiology , Abnormalities, Multiple/chemically induced , Angiotensin Receptor Antagonists , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Fetal Diseases/chemically induced , Abnormalities, Drug-Induced/pathology , Abnormalities, Multiple/pathology , Adult , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Contraindications , Female , Fetal Diseases/enzymology , Fetal Diseases/pathology , Humans , Hypertension/drug therapy , Pregnancy , Pregnancy Complications, Cardiovascular/drug therapy , Renin-Angiotensin System/drug effects
14.
J Matern Fetal Neonatal Med ; 29(18): 3003-8, 2016 Sep.
Article in English | MEDLINE | ID: mdl-26513600

ABSTRACT

OBJECTIVES: There is growing evidence of ongoing, in utero neurological damage in fetuses with myelomeningocele (MMC). Phospholipase A2 (PLA2) has known neurotoxic properties and is predominantly present in its secretory isoform (sPLA2) in meconium, the passage of which is increased in MMC fetuses. The objective of this study was to determine if amniotic fluid (AF) levels of PLA2 are elevated in a rat model of MMC. METHODS: Timed pregnant Sprague-Dawley rats were gavage fed 60 mg/kg/bodyweight retinoic acid (RA) in olive oil at embryonic day 10 (E10). Amniocentesis was performed at multiple gestational time points on MMC fetuses, RA-exposed fetuses without MMC and control fetuses. AF PLA2 levels were analyzed by a fluorescent enzyme activity assay. PLA2 isoforms were determined by measuring activity in the presence of specific inhibitors. RESULTS: There was no difference in AF PLA2 activity between groups on E15. PLA2 activity was significantly increased in MMC fetuses on E17, E19 and E21 (p < 0.001). Secretory PLA2 primarily accounted for the overall greater activity. CONCLUSIONS: PLA2 levels are elevated in the AF of fetal rats with MMC and may contribute to ongoing neural injury. This pathway may be a useful drug target to limit ongoing damage and better preserve neurologic function.


Subject(s)
Amniotic Fluid/enzymology , Fetal Diseases/enzymology , Meningomyelocele/enzymology , Phospholipases A2, Secretory/metabolism , Animals , Disease Models, Animal , Female , Fetal Diseases/chemically induced , Fluorescent Antibody Technique , Isoenzymes/metabolism , Meningomyelocele/chemically induced , Pregnancy , Rats , Rats, Sprague-Dawley , Tretinoin
16.
Nat Commun ; 6: 8825, 2015 Nov 23.
Article in English | MEDLINE | ID: mdl-26593099

ABSTRACT

Striated preferentially expressed gene (Speg) is a member of the myosin light chain kinase family. We previously showed that disruption of the Speg gene locus in mice leads to a dilated cardiomyopathy with immature-appearing cardiomyocytes. Here we show that cardiomyopathy of Speg(-/-) mice arises as a consequence of defects in cardiac progenitor cell (CPC) function, and that neonatal cardiac dysfunction can be rescued by in utero injections of wild-type CPCs into Speg(-/-) foetal hearts. CPCs harvested from Speg(-/-) mice display defects in clone formation, growth and differentiation into cardiomyocytes in vitro, which are associated with cardiac dysfunction in vivo. In utero administration of wild-type CPCs into the hearts of Speg(-/-) mice results in CPC engraftment, differentiation and myocardial maturation, which rescues Speg(-/-) mice from neonatal heart failure and increases the number of live births by fivefold. We propose that in utero administration of CPCs may have future implications for treatment of neonatal heart diseases.


Subject(s)
Cardiomyopathies/therapy , Cell- and Tissue-Based Therapy , Fetal Diseases/therapy , Fetal Therapies , Myocytes, Cardiac/transplantation , Animals , Cardiomyopathies/embryology , Cardiomyopathies/enzymology , Cardiomyopathies/physiopathology , Cell Differentiation , Female , Fetal Diseases/enzymology , Fetal Diseases/genetics , Fetal Diseases/physiopathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Muscle Proteins/genetics , Muscle Proteins/metabolism , Myocytes, Cardiac/cytology , Myocytes, Cardiac/enzymology , Myosin-Light-Chain Kinase/genetics , Myosin-Light-Chain Kinase/metabolism , Pregnancy , Stem Cell Transplantation , Stem Cells/cytology , Stem Cells/enzymology , Uterus
17.
Hum Gene Ther ; 13(15): 1809-20, 2002 Oct 10.
Article in English | MEDLINE | ID: mdl-12396614

ABSTRACT

Canine alpha-L-iduronidase (alpha-ID) deficiency is caused by a single base pair mutation in the alpha-ID gene, resulting in no enzyme activity in homozygous affected pups. The disease clinically resembles human mucopolysaccharidosis type I (MPSI). We used the canine MPSI model system to address the efficacy of a new retroviral vector, MND-MFG, containing the human alpha-ID cDNA (MND-MFG-alpha-ID) for direct in utero gene delivery to MPSI cells. In vitro, the MND-MFG-alpha-ID vector showed high-level, long-term expression of the transgene in both canine and human alpha-ID-deficient fibroblasts. The effectiveness of this vector for in utero gene transfer and expression in multiple tissues was assessed by injecting viral supernatants into MPSI fetuses and evaluating transduction efficiency and enzyme expression at various times after birth. Transduction of a spectrum of cell types and tissues was observed in all seven live-born pups and in one stillborn pup. Although enzyme activity was not detected in adult tissues from the seven surviving pups, significant alpha-ID enzyme activity was detected in both the liver and kidney of the deceased pup. Our combined gene delivery vector and in utero transfer approach, while encouraging in terms of overall gene transfer efficiency to multiple tissues and successful short-term gene expression, was unable to meet the important requirement of sustained in vivo gene expression.


Subject(s)
Fetal Diseases/therapy , Genetic Therapy , Genetic Vectors/administration & dosage , Iduronidase/genetics , Mucopolysaccharidosis I/therapy , Animals , Animals, Newborn , Cells, Cultured , DNA, Complementary/administration & dosage , DNA, Complementary/genetics , DNA, Complementary/therapeutic use , Disease Models, Animal , Dogs , Female , Fetal Diseases/enzymology , Fibroblasts/enzymology , Gene Expression Regulation, Developmental , Gene Expression Regulation, Enzymologic , Genetic Vectors/therapeutic use , Humans , Iduronidase/deficiency , Injections , Injections, Intraperitoneal , Jurkat Cells/enzymology , Kidney/enzymology , Liver/enzymology , Mucopolysaccharidosis I/embryology , Mucopolysaccharidosis I/enzymology , Mucopolysaccharidosis I/genetics , Pregnancy , Tissue Distribution , Transduction, Genetic , Yolk Sac
18.
J Clin Endocrinol Metab ; 81(6): 2154-8, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8964844

ABSTRACT

Thyroid hormones are essential for fetal development. T4 can be activated by type I (ID-I) and type II (ID-II) iodothyronine deiodinase or inactivated by type III deiodinase (ID-III). The influence of placental ID-II and ID-III on the regulation of fetal thyroid hormone levels was investigated. Using [125I]T4 and [125I]T3, respectively, ID-II and ID-III activities were measured in homogenates of normal human placentas from 6-43 weeks gestational age and in placentas from five term neonates with a total thyroid hormone synthesis defect. ID-II and ID-III activities related to protein or DNA concentration decreased and total placental ID-III activity increased significantly during pregnancy, whereas the increase in total placental ID-II activity was not significant. Absolute placental ID-II activity was approximately 200 times lower than ID-III activity at all gestational ages. Therefore, fluctuations in ID-II activity were not likely to have a significant influence on fetal thyroid hormone concentrations, but may play a role in the regulation of intraplacental T3 generation. The high ID-III activity most likely influences the thyroid hormone economy of the fetus. Severely hypothyroid newborns showed strongly decreased serum T4 levels, but serum T3 and placental ID-III activities were similar to those in euthyroid newborns. These results suggest that placental ID-III activity is regulated by serum T3, but not by serum T4.


Subject(s)
Gestational Age , Iodide Peroxidase/metabolism , Isoenzymes/metabolism , Placenta/enzymology , Female , Fetal Diseases/enzymology , Humans , Hypothyroidism/enzymology , Pregnancy
19.
J Clin Endocrinol Metab ; 58(3): 574-7, 1984 Mar.
Article in English | MEDLINE | ID: mdl-6607266

ABSTRACT

The characteristic excess production of androgens in the cortisol 21-hydroxylase defect is generally considered to be secondary to ACTH stimulation of alternate pathways. Whenever a morphological examination of the adrenals has been possible in this disorder, adrenocortical hyperplasia was a constant finding. The availability of methods for the prenatal diagnosis of the 21-hydroxylase defect has made it possible to examine some of the manifestations of this disorder during fetal life. We studied a severely virilized 20-week-old aborted female fetus with the 21-hydroxylase defect whose adrenals were neither grossly enlarged nor microscopically hyperplastic. In a pregnancy at risk for congenital adrenal hyperplasia due to a 21-hydroxylase deficiency, amniocentesis was performed in the 18th week of gestation. The 21-hydroxylase defect was established by HLA typing and highly elevated levels of 17-hydroxyprogesterone, testosterone, and androstendione in amniotic fluid. After counselling, the parents, who already had a girl with the salt-wasting form of 21-hydroxylase deficiency, wished termination of the pregnancy. The aborted 20-week-old fetus was within the normal range for gestational age in weight and height. The external genitalia were ambiguous and extremely virilized, with an enlarged clitoris and fused labioscrotal folds. A urogenital sinus opened at the base of the clitoris. The internal organs were female, with a normal uterus and ovaries. Both adrenals were normal in size and weight for their gestational age. Histological examination of the adrenals revealed no abnormalities, and no hyperplasia was detectable. Thus, the adrenals in the 21-hydroxylase defect during fetal life secrete excessive amounts of androgens and cause virilization in the absence of adrenocortical hyperplasia.


Subject(s)
Adrenal Hyperplasia, Congenital/complications , Fetal Diseases/enzymology , Steroid Hydroxylases/deficiency , Virilism/enzymology , Female , Fetal Diseases/genetics , Fetal Diseases/pathology , HLA Antigens/analysis , Humans , Karyotyping , Pregnancy , Virilism/embryology , Virilism/pathology
20.
Arch Neurol ; 43(7): 736-8, 1986 Jul.
Article in English | MEDLINE | ID: mdl-3089200

ABSTRACT

A 24-week fetus with GM1 gangliosidosis (type 1) was studied using biochemical and histopathologic methods. Foam cells in viscera and placenta demonstrated widespread accumulation of a lipidlike material. By microscopy, central nervous system storage appeared confined to the retina and dorsal root ganglia, but the brain ganglioside content was measurably elevated compared with that of age-matched controls. These data, along with those of others, imply that, if the observed pathologic findings are irreversible, any attempts at intrauterine therapy must commence prior to the middle of the second trimester.


Subject(s)
Fetal Diseases/pathology , Gangliosidoses/pathology , Abortion, Induced , Adult , Amniocentesis , Brain/metabolism , Brain/pathology , Female , Fetal Diseases/diagnosis , Fetal Diseases/enzymology , G(M1) Ganglioside , Gangliosidoses/diagnosis , Gangliosidoses/enzymology , Humans , Kidney/pathology , Pregnancy , beta-Galactosidase/deficiency
SELECTION OF CITATIONS
SEARCH DETAIL